NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company announced that it plans to initiate a Phase 1/2a clinical trial on acute spinal cord injuries for ExoPTEN in 2026. This marks a significant step forward and provides hope for thousands of patients.
